RSV Vaccine Candidates Thwarted Severe Illness In Older Adults, Trials Show

October 27, 2022

MedPage Today (10/26, Hein) reports, “Prefusion F protein vaccine candidates for respiratory syncytial virus (RSV) proved safe in adults 60 and up while demonstrating an ability to thwart lower respiratory tract illness, including severe cases, a pair of...